Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis

Fig. 1

Differences in mean TB-related costs per new TB patient between the new 4 four-month regimen and the six-month regiment, by country, scenario, and payer. Difference of means – negative number refers to cost savings of introducing a shortened regimen compared to baseline (standard treatment). Health services costs are calculated assuming a drug price for the shortened regime of 1USD. These costs do not include ART-related costs. We define the societal perspective as the sum of health service and patient (and their households) perspectives. In the case of South Africa (current scenario) and Tanzania (current and guidelines scenario), the societal perspective costs are very close to cost neutral

Back to article page